Leerink Partnrs Issues Optimistic Outlook for REGN Earnings

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) - Leerink Partnrs raised their Q4 2024 earnings estimates for Regeneron Pharmaceuticals in a research note issued on Tuesday, January 28th. Leerink Partnrs analyst D. Risinger now anticipates that the biopharmaceutical company will post earnings per share of $9.82 for the quarter, up from their prior forecast of $8.81. The consensus estimate for Regeneron Pharmaceuticals' current full-year earnings is $37.74 per share. Leerink Partnrs also issued estimates for Regeneron Pharmaceuticals' Q1 2025 earnings at $6.80 EPS and FY2025 earnings at $33.55 EPS.

REGN has been the topic of a number of other research reports. Canaccord Genuity Group assumed coverage on Regeneron Pharmaceuticals in a report on Tuesday, December 17th. They set a "hold" rating and a $165.00 price objective on the stock. Piper Sandler cut their price target on shares of Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an "overweight" rating for the company in a report on Monday, January 27th. Canaccord Genuity Group cut shares of Regeneron Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, December 17th. StockNews.com lowered shares of Regeneron Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research report on Monday, November 4th. Finally, Sanford C. Bernstein reduced their price target on shares of Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an "outperform" rating for the company in a research report on Tuesday, January 7th. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating, fifteen have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $1,004.57.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN stock traded down $10.10 during trading hours on Thursday, reaching $672.98. 943,776 shares of the company's stock were exchanged, compared to its average volume of 802,652. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.28 and a quick ratio of 4.46. The company's 50 day moving average is $720.81 and its two-hundred day moving average is $922.87. The company has a market cap of $73.95 billion, a P/E ratio of 16.65, a price-to-earnings-growth ratio of 1.62 and a beta of 0.10. Regeneron Pharmaceuticals has a 1 year low of $666.25 and a 1 year high of $1,211.20.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of REGN. Rakuten Securities Inc. lifted its stake in shares of Regeneron Pharmaceuticals by 380.0% during the 3rd quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company's stock worth $25,000 after purchasing an additional 19 shares during the period. FSA Wealth Management LLC acquired a new position in Regeneron Pharmaceuticals in the third quarter valued at $26,000. Fairfield Financial Advisors LTD purchased a new position in Regeneron Pharmaceuticals during the third quarter worth about $37,000. Private Wealth Management Group LLC boosted its stake in Regeneron Pharmaceuticals by 260.0% in the 4th quarter. Private Wealth Management Group LLC now owns 54 shares of the biopharmaceutical company's stock worth $38,000 after buying an additional 39 shares during the last quarter. Finally, Truvestments Capital LLC purchased a new stake in Regeneron Pharmaceuticals in the 3rd quarter valued at about $39,000. Hedge funds and other institutional investors own 83.31% of the company's stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.